Business
Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer
Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded Repertoire® Immune Medicines will identify and optimize TCR bispecifics for metastatic prostate cancer.
About this update from Pfizer, Inc.
[{"type":"text","content":"Repertoire and Pioneering Medicines, Flagship's in-house drug development unit, will jointly conduct research activities leveraging Repertoire's DECODE™ platform","length":169,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced a research program under its strategic collaboration with Pfizer whereby Flagship-founded Repertoire® Immune Medicines will identify and optimize TCR bispecifics for metastatic prostate cancer.","length":362,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Flagship Pioneering)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Flagship Pioneering)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":158,"url":"https://media.zenfs.com/en/prnewswire.com/1a51427c584f846361c98bc2eeb40827"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/K.WUW_4wdw8Duqc.YgOACA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI3ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1a51427c584f846361c98bc2eeb40827","width":400,"height":158}},"href":"https://mma.prnewswire.com/media/2156098/Flagship_Pioneering_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Pioneering Medicines, Flagship's in house drug discovery and development unit, is responsible for leading the strategic partnership with Pfizer, including driving the exploration process to rapidly surface potential drug development programs built on Flagship's diverse bioplatforms and modalities. The Repertoire agreement is the eighth program initiated under Flagship's strategic partnership with Pfizer announced in July 2023.","length":442,"tagName":"p"},{"type":"text","content":""Repertoire's DECODE platform uniquely maps the entire immune synapse, presenting enormous uncharted potential to discover new antigens capable of activating the immune system to fight cancer, and when coupled with Repertoire's immune medicine engineering technologies and capabilities, places us in a strong position to generate targeted medicines to engage them," said Torben Straight Nissen, Ph.D., Chairman and CEO of Repertoire and Executive Partner at Flagship Pioneering. "Guided by Pfizer's drug development expertise in oncolo...